Screener
Castle Biosciences CSTL PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| ASSETS | March 31, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Prepaid expenses and other current assets | 14,491 | 7,956 |
| Total current assets | 328,901 | 361,097 |
| Long-term accounts receivable, net | 1,921 | 1,878 |
| Property and equipment, net | 100,934 | 97,443 |
| Operating lease assets | 14,424 | 14,795 |
| Goodwill and other intangible assets, net | 97,347 | 99,574 |
| Other assets – long-term | 4,278 | 3,769 |
| Total assets | $547,805 | $578,556 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's PP&E (net)?
- Castle Biosciences (CSTL) reported PP&E (net) of $100.93M in Q1 2026.
- How has Castle Biosciences's PP&E (net) changed year-over-year?
- Castle Biosciences's PP&E (net) increased by 82.1% year-over-year, from $55.42M to $100.93M.
- What is the long-term trend for Castle Biosciences's PP&E (net)?
- Over 5 years (2020 to 2025), Castle Biosciences's PP&E (net) has grown at a 68.8% compound annual growth rate (CAGR), from $7.1M to $97.44M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Castle Biosciences's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude